The FDA has approved orforglipron (Foundayo), a once-daily oral medication for adults with obesity or who are overweight and have weight-related medical conditions. This marks a significant step forward in accessible weight-loss treatments, offering a new option beyond injectable medications and providing a different administration route for those who prefer a pill. The approval of orforglipron likewise represents a speed record for new drug approvals, signaling a potential shift in how the agency evaluates and prioritizes certain medications.
Unlike its counterpart, oral semaglutide (Wegovy), orforglipron doesn’t require specific timing with food or water intake, offering greater flexibility for patients. This convenience could improve adherence, a common challenge with chronic medications. The demand for effective weight-loss treatments is substantial, driven by the rising rates of obesity and its associated health risks, including heart disease, type 2 diabetes, and certain cancers. The availability of more options, like orforglipron, aims to address this growing public health concern.
Fast-Tracked Approval and the National Priority Voucher Program
The FDA granted orforglipron approval in just 50 days after the application was filed, a remarkably swift process. This expedited review was made possible by the agency’s National Priority Voucher program, as announced by the FDA. The program is designed to incentivize the development of drugs that address unmet medical needs, particularly those related to serious conditions. This is the first approval of a new molecular entity under this program since 2002, highlighting the agency’s commitment to accelerating the availability of innovative therapies.
The voucher program allows pharmaceutical companies to receive a priority review voucher for developing drugs targeting specific diseases. These vouchers can then be redeemed for a faster review of a different drug application, or they can be sold to other companies. Eli Lilly, the manufacturer of orforglipron, obtained this voucher through prior operate on a different drug addressing a neglected tropical disease.
Clinical Trial Results: Weight Loss and Metabolic Improvements
The approval of orforglipron was based on data from two phase 3 clinical trials, ATTAIN-1 and ATTAIN-2, involving over 4,500 participants. Results published in The Lancet demonstrated significant reductions in body weight, as well as improvements in metabolic health markers. Patients receiving the highest tested dose (36 mg) lost an average of 9.6% to 11.2% of their body weight over 72 weeks – roughly 23 to 25 pounds.
Though, it’s important to note that the approved dosage is lower, at a maximum of 17.2 mg daily. Clinical trials using the 12-mg pill showed an average weight loss of 7% to 8.4% at week 72. Even as effective, this is less than the 13.6% average weight loss observed in the OASIS 4 trial with the maximum dose (25 mg) of oral semaglutide, according to MedPage Today. The difference underscores the varying efficacy of different GLP-1 receptor agonists and the importance of individualized treatment plans.
Safety and Potential Side Effects
As with other GLP-1 receptor agonists like semaglutide and tirzepatide (Zepbound), orforglipron carries a boxed warning regarding the potential risk of thyroid C-cell tumors. The medication is not recommended for individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Common side effects observed in clinical trials included nausea, constipation, diarrhea, vomiting, indigestion, stomach pain, headache, abdominal distension, fatigue, belching, heartburn, flatulence, and hair loss.
Patients should also be aware of potential risks such as pancreatitis, severe gastrointestinal reactions, acute kidney injury due to dehydration, hypoglycemia, and hypersensitivity. Orforglipron should not be used in combination with other GLP-1 receptor agonists. A cardiovascular outcomes study is currently underway (NCT07241390) to further evaluate the long-term safety and efficacy of the drug.
Availability and Cost
Eli Lilly announced that orforglipron will be available beginning next Monday. The drug will be accessible through retail pharmacies, telehealth providers, and LillyDirect, the company’s direct-to-patient service. Pricing will vary depending on insurance coverage. With commercial insurance, LillyDirect will offer the medication for $25 per month. Cash-paying patients can access it for $149 per month, and eligible Medicare Part D enrollees may be able to obtain it for $50 per month starting in July.
Beyond weight loss, Eli Lilly is also investigating orforglipron as a potential treatment for type 2 diabetes, obstructive sleep apnea, osteoarthritis knee pain, hypertension, peripheral artery disease, and stress urinary incontinence, as reported by MedPage Today. These ongoing studies could broaden the therapeutic applications of this novel medication.
Disclaimer: This article provides information for general knowledge and informational purposes only, and does not constitute medical advice. It is essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
The rollout of orforglipron marks a new chapter in obesity treatment, offering a convenient oral option for those seeking weight management solutions. The ongoing cardiovascular outcomes study will provide further insights into the long-term effects of the drug, and continued research may reveal additional therapeutic benefits. The FDA will continue to monitor the safety and efficacy of orforglipron as it becomes more widely available.
Have thoughts on this new treatment option? Share your comments below, and please consider sharing this article with your network.
